Recent advances in imaging hepatocellular carcinoma: Diagnosis, staging and response assessment: Functional imaging

Cancer Journal

Volumn 10, Issue 2, 2004, Pages 121-127

  Hain, S F ^a,b   Fogelman, I ^a,b  

^a Guy's and St Thomas Hospital and King's College ^*

^b GUY S HOSPITAL   (United Kingdom)

Author keywords

FDG; Hepatic cancer; PET

Indexed keywords

FLUORODEOXYGLUCOSE; DIAGNOSTIC AGENT; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; HUMAN; LIVER CELL CARCINOMA; LIVER TUMOR; PORTAL PHLEBOGRAPHY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; COMPUTER ASSISTED EMISSION TOMOGRAPHY;

CARCINOMA, HEPATOCELLULAR; FLUORODEOXYGLUCOSE F18; HUMANS; LIVER NEOPLASMS; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 4544313522     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/00130404-200403000-00007     Document Type: Review

References (44)

1. Rabinowitz I, Telpak R, Lee FC. Octreotide scans are positive in a subset of patients with hepatocellular carcinoma. Clin Nucl Med 2002;27:499-502.
2. Wang SJ, Lin WY, Wey SP et al. Pentavalent Tc-99m dimercaptosuccinic acid imaging of hepatocellular carcinoma. Neoplasma 1999;46:246-248.
3. Saito K, Koizumi K, Abe K et al. Potential for qualitative diagnosis of tumors and tumorous lesions in the liver with Tc-99m-GSA SPECT-correlation with pathological evaluation and MRI findings. Ann Nucl Med 1998;12:275-280.
4. Akaki S, Mitsumori A, Kanazawa S et al. Technetium-99m-DTPA-galactosyl human serum albumin liver scintigraphy evaluation of regional CT/MRI attenuation/signal intensity differences. J Nucl Med 1998;39:529-532.
5. Hama Y, Kosuda S, Iwasaki Y et al. Technetium Tc 99m DTPA galactosyl human serum albumin to measure changes in hepatic functional reserve after transcatheter arterial embolization of the liver. Can Assoc Radiol J 2001;52:399-403.
6. Kira T, Tomiguchi S, Takahashi M. Quantitative evaluation of the regional hepatic reserve by 99m TC-GSA dynamic SPECT before and after chemolipiodolization in patients with hepatocellular carcinoma. Ann Nucl Med 1998;12:369-373.
7. Mochizuki T, Tsuda T, Sugawara Y et al. Tc-99m PMT hepatobiliary scintigraphy in the differential diagnosis of extrahepatic metastases and hepatocellular carcinoma. Clin Nucl Med 2000;25:991-995.
8. Fukutomi M, Yokota M, Chuman H et al. Increased incidence of bone metastases in hepatocellular carcinoma. Eur J Gastroenterol Hepatol 2001;13:1083-1088.
9. Okuda K, Ohtsuki T, Obata H et al. Natural history of hepatocellular carcinoma and progress in relation to treatment. Cancer 1985;56:918-921.
10. Leung WT, Lau WY, Ho M et al. Selective internal radiation therapy with intra-arterial iodine-131-lipiodol in inoperable hepatocellular carcinoma. J Nucl Med 1994;35:1313-1318.
11. Brans B, De Winter F, Deferene L et al. Neo-adjuvant treatment of hepatocellular carcinoma (HCC) with intra-arterial I-131 Lipiodol therapy. Eur J Nucl Med 2000;27:941.
12. Veihlan LE, Boucher E, Raoul JL et al. Prevention of recurrence of hepatocellular carcinoma after orthotopic liver transplantation by neo-adjuvant intra-arterial injection of iodine-131 labeled lipiodol: results of a pilot study. Eur J Nucl Med 2000;27:941.
13. Roul JL, Guyander D, Bretagne JF et al. Prospective randomised trial of chemoembolisation versus intra-arterial iodine-131 lipiodol in inoperable hepatocellular carcinoma. Hepatology 1997;26:1156-1161.
14. Okuda K, Ohtsuki T, Obata H et al. Natural history of hepatocellular carcinoma and progress in relation to treatment. Cancer 1985;56:918-921.
15. Bhattacharya S, Novell JR, Dusheiko GM et al. Epirubicin-lipiodol chemotherapy vs. I-131 iodine lipiodol radiotherapy in the treatment of unresectable hepatocellular carcinoma. Cancer 1995;76:2202-2210.
16. Lau WY, Leung WT, Ho S et al. Treatment of inoperable hepatocellular carcinoma with intrahepatic arterial yttrium-90 microspheres-a phase I and II study. Br J Cancer 1994;70:994-999.
17. Buscombe JR, Padhy AK. Treatment of hepatocellular carcinoma: a pivotal role for nuclear medicine. Nucl Med Commun 2001;22:119-120.
18. Saunders CA, Dussek JE, O'Doherty MJ et al. Evaluation of fluorine-18-fluorodeoxyglucose whole body positron emission tomography imaging in the staging of lung cancer. Ann Thorac Surg 1999;67:790-797.
19. Mikhaeel NG, Timothy AR, HainS et al. 18-FDG-PET as a prognostic indicator in the treatment of aggressive non-Hodgkin's lymphoma. Leukaemia Lymphoma 2000;39:543-553.
20. Hain SF, O'Doherty MJ, Timothy AR et al. Fluorodeoxyglucose positron emission tomography in the evaluation of germ cell tumours at relapse. Br J Cancer 2000;83:863-869.
21. Mikhaeel NG, Timothy AR, Hain SF et al. 18F FDG-PET for the assessment of residual masses on CT after treatment of lymphomas. Ann Oncol 2000;11:5147-5150.
22. Schelling M, Avril N, Nahrig J et al. Positron emission tomography using [(18) F] fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol 2000;18:1689-1695.
23. Weber G, Cantero A. Glucose-6-phosphatase activity in normal, precancerous and neoplastic tissue. Cancer Res 1955;15:105-108.
24. Weber G, Morris HP. Comparative biochemistry of hepatomas: carbohydrate enzymes in liver tumours of different growth rates. Cancer Res 1963;23:987-994.
25. Wudel LJ Jr, Delbeke D, Morris D et al. The role of [18F] fluorodeoxyglucose positron emission tomography imaging in the evaluation of hepatocellular carcinoma. Am Surg 2003;69:117-124.
26. Trojan J, Schroeder O, Raedle J et al. Fluorine-18 FDG positron emission tomography for imaging of hepatocellular carcinoma. Am J Gastroenterol 1999;94:3314-3319.
27. Delbeke D, Martin WH, Sandler MP et al. Evaluation of benign vs. malignant hepatic lesions with positron emission tomography. Arch Surg 1998;133:510-515.
28. Schroder O, Trojan J, Zeuzem S et al. Limited value of fluorine-18-fluorodeoxyglucose PET for the differential diagnosis of focal liver lesions in patients with chronic hepatitis C virus infection. Nuklearmedizin 1998;37:279-285.
29. Teefey SA, Hildeboldt CC, Dehdashti F et al. Detection of primary hepatic malignancy in liver transplant candidates: prospective comparison of CT, MR imaging, US and PET. Radiology 2003;226:533-542.
30. Khan MA, Combs CS, Brunt EM et al. Positron emission tomography scanning in the evaluation of hepatocellular carcinoma. J Hepatol 2000;32:792-797.
31. Torizuka T, Tamaki N, Inokuma T et al. In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG-PET. J Nucl Med 1995;36:1811-1817.
32. Lodge MA, Lucas JD, Marsden PK et al. A PET study of 18FDG uptake in soft tissue masses. Eur J Nucl Med 1999;26:22-30.
33. Kubota K, Itoh M, Ozaki K et al. Advantage of delayed wholebody FDG-PET imaging for tumour detection. Eur J Nucl Med 2001;28:696-703.
34. Koyama K, Okamura T, Kawabe J et al. The usefulness of 18F-FDG PET images obtained 2 hours after intravenous injection in liver tumor. Ann Nucl Med 2002;16:169-176.
35. 11C-acetate PET imaging of prostate cancer. J Nucl Med 2002;43:181-186.
36. Ho CL, Yu SC, Yeung DW. 11C-acetate PET imaging in hepatocellular carcinoma and other liver masses. J Nucl Med 2003;44:213-221.
37. Koh T, Taniguchi H, Yamagishi H. Oxygen-15 positron-emission tomography for predicting selective delivery of a chemotherapeutic agent to hepatic cancers during angiotensin H-induced hypertension. Cancer Chemother Pharmacol 2003;51:349-358.
38. Morikawa H, Shiomi S, Sasaki N et al. Hepatocellular carcinoma monitored by F-18 fluorodeoxyglucose positron emission tomography after laparoscopic microwave coagulation therapy. Clin Nucl Med 1999;24:536-538.
39. Torizuka T, Tamaki N, Inokuma T et al. Value of fluorine-18-FDG PET to monitor hepatocellular carcinoma after interventional therapy. J Nucl Med 1994;35:11965-11969.
40. Akuta K, Nishimura T, Jo S et al. Monitoring liver tumour therapy with [18F]FDG positron emission tomography. J Comput Assist Tomogr 1990;14:370-374.
41. Vitola JV, Delbeke D, Meranze SG et al. Positron emission tomography with F-18-fluorodeoxyglucose to evaluate the results of hepatic embolisation. Cancer 1996;78:2216-2222.
42. Shimi S, Nishiguchi S, Ishizy H et al. Usefulness of positron emission tomography with fluorodeoxyglucose for predicting outcome in patients with hepatocellular carcinoma. Am J Gastroenterol 2001;96:1877-1880.
43. Dhital K, Saunders CA, Seed PT et al. [(18)F] Fluorodeoxyglucose positron emission tomography and its prognostic value in lung cancer. Eur J Cardiothorac Surg 2000;18:425-428.
44. Halfpenny W, Hain SF, Biassoni L et al. FDG-PET. A possible prognostic factor in head and neck cancer Br J Cancer 2002;86:512-516.